In our previous work (15), we developed a comprehensive pipeline to identify and characterize naturally occurring TCRs specific to the HER2/neu tumor-associated antigen, aiming to enhance the development of TCR-T cell therapies for solid tumors. Here, ERBB2 is linked to neoplasm.